TY - JOUR
T1 - Phytomedicines targeting cancer stem cells
T2 - Therapeutic opportunities and prospects for pharmaceutical development
AU - Gupta, Piyush Kumar
AU - Saraff, Mrunmayee
AU - Gahtori, Rekha
AU - Negi, Nidhi
AU - Tripathi, Surya Kant
AU - Kumar, Jatin
AU - Kumar, Sanjay
AU - Aldhayan, Saad Hamad
AU - Dhanasekaran, Sugapriya
AU - Abomughaid, Mosleh Mohammad
AU - Dua, Kamal
AU - Gundamaraju, Rohit
AU - Ojha, Shreesh
AU - Ruokolainen, Janne
AU - Jha, Niraj Kumar
AU - Kesari, Kavindra Kumar
N1 - Funding Information:
This research did not receive any specific grant from the funding agencies in the public, commercial, or not-for-profit sectors. The APC was paid by K.K.K. and J.R. (Department of Applied Physics, Aalto University, Finland).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7
Y1 - 2021/7
N2 - The presence of small subpopulations of cells within tumor cells are known as cancer stem cells (CSCs). These cells have been the reason for metastasis, resistance with chemotherapy or radiotherapy, and tumor relapse in several types of cancers. CSCs underwent to epithelial– mesenchymal transition (EMT) and resulted in the development of aggressive tumors. CSCs have potential to modulate numerous signaling pathways including Wnt, Hh, and Notch, therefore increasing the stem-like characteristics of cancer cells. The raised expression of drug efflux pump and suppression of apoptosis has shown increased resistance with anti-cancer drugs. Among many agents which were shown to modulate these, the plant-derived bioactive agents appear to modulate these key regulators and were shown to remove CSCs. This review aims to comprehensively scrutinize the preclinical and clinical studies demonstrating the effects of phytocompounds on CSCs isolated from various tumors. Based on the available convincing literature from preclinical studies, with some clinical data, it is apparent that selective targeting of CSCs with plants, plant preparations, and plant-derived bioactive compounds, termed phytochemicals, may be a promising strategy for the treatment of relapsed cancers.
AB - The presence of small subpopulations of cells within tumor cells are known as cancer stem cells (CSCs). These cells have been the reason for metastasis, resistance with chemotherapy or radiotherapy, and tumor relapse in several types of cancers. CSCs underwent to epithelial– mesenchymal transition (EMT) and resulted in the development of aggressive tumors. CSCs have potential to modulate numerous signaling pathways including Wnt, Hh, and Notch, therefore increasing the stem-like characteristics of cancer cells. The raised expression of drug efflux pump and suppression of apoptosis has shown increased resistance with anti-cancer drugs. Among many agents which were shown to modulate these, the plant-derived bioactive agents appear to modulate these key regulators and were shown to remove CSCs. This review aims to comprehensively scrutinize the preclinical and clinical studies demonstrating the effects of phytocompounds on CSCs isolated from various tumors. Based on the available convincing literature from preclinical studies, with some clinical data, it is apparent that selective targeting of CSCs with plants, plant preparations, and plant-derived bioactive compounds, termed phytochemicals, may be a promising strategy for the treatment of relapsed cancers.
KW - Clinical research
KW - Epithelial–mesenchymal transition
KW - Phytochemicals
KW - Phytomedicines
KW - Preclinical
KW - Signaling pathway
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=85111106494&partnerID=8YFLogxK
U2 - 10.3390/ph14070676
DO - 10.3390/ph14070676
M3 - Review Article
AN - SCOPUS:85111106494
SN - 1424-8247
VL - 14
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 7
M1 - 676
ER -
